These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35232995)

  • 41. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 43. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
    Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
    Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
    Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
    Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
    Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
    Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
    Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
    Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
    Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
    Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
    Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
    Greenblatt S; Li L; Slape C; Nguyen B; Novak R; Duffield A; Huso D; Desiderio S; Borowitz MJ; Aplan P; Small D
    Blood; 2012 Mar; 119(12):2883-94. PubMed ID: 22323452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
    Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
    Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.